Telix Announces Licence Agreement with Lilly for Olaratumab
Telix announces a licence agreement for Lilly’s olaratumab antibody, for diagnosis and treatment of human cancers.
Telix is pleased to announce that it has entered into a licence…
Read More...
Read More...
